SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease

Results from recent randomized controlled trials on inhibitors of the sodium-glucose cotransporter 2 (SGLT2) have determined a paradigm shift in the treatment of patients with type 2 diabetes mellitus. These agents have been shown not only to ameliorate metabolic control, but also to independently p...

Descripción completa

Detalles Bibliográficos
Autores principales: Podestà, Manuel Alfredo, Sabiu, Gianmarco, Galassi, Andrea, Ciceri, Paola, Cozzolino, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953060/
https://www.ncbi.nlm.nih.gov/pubmed/36830815
http://dx.doi.org/10.3390/biomedicines11020279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953060/
https://www.ncbi.nlm.nih.gov/pubmed/36830815
http://dx.doi.org/10.3390/biomedicines11020279

Ejemplares similares